MUNICH, Germany—Long-term follow-up from the Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) trial confirm the results observed at 30 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results